Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways. The company's proprietary platform enables the discovery and development of small molecules that bind covalently to proteins. Revolution Medicines was founded in 2014 and is headquartered in South San Francisco, California.